Literature DB >> 34475640

Assessment of chitosan nanoparticles in improving the efficacy of nitazoxanide on cryptosporidiosis in immunosuppressed and immunocompetent murine models.

Howayda Said Fouad Moawad1, Mohamed Hegab Abd El-Hady Hegab1, Maha Saber Reda Badawey1, Shaimaa Elsayed Ashoush1, Shereen Mahmoud Ibrahim1, Amira Abd El-Lateef Saleh Ali1.   

Abstract

Cryptosporidiosis is one of the major causes of diarrhea in immunocompetent and immunocompromised patients. It is self-limited in immunocompetent individuals. However, in the immunocompromised it can cause life-threatening diarrhea and results in chronic malabsorption of fluids, vitamins and electrolytes resulting in wasting. Our study is concerned with assessing and comparing the efficacy of nitazoxanide (NTZ) alone and NTZ loaded chitosan nanoparticles (NTZ loaded CS NPs) in the treatment of experimental cryptosporidiosis using parasitological and histopathological parameters. One hundred mice were divided into 5 groups (20 mice each). Each group was divided into 2 subgroups according to the immune status [a-immunocompetent, b-immunosuppressed]. group 1: control (healthy), group 2: control infected by Cryptosporidium oocysts, group 3: infected treated by NTZ, group 4: infected then treated by NTZ loaded CS NPs and group 5: infected then treated by chitosan nanoparticles (CS NPs) alone. Treatment of Cryptosporidium infected mice with NTZ loaded on CS NPs resulted in the highest significant reduction in oocysts shedding in both immunocompetent and immunosuppressed groups followed by treatment with NTZ form then by treatment with CS NPs alone. The treatment with NTZ loaded CS NPs displayed a remarkable improvement of the histopathological changes of the intestine, liver and lung while NTZ treated group showed some improvement. Treatment with NTZ loaded CS NPs in murine cryptosporidiosis gave the best results as it caused marked reduction in fecal oocysts counts and improvement of histopathological changes in immunocompetent and immunosuppressed groups. © Indian Society for Parasitology 2021.

Entities:  

Keywords:  Chitosan nanoparticles; Cryptosporidium; Immunocompetent and immunosuppression; Nitazoxanide

Year:  2021        PMID: 34475640      PMCID: PMC8368908          DOI: 10.1007/s12639-020-01337-y

Source DB:  PubMed          Journal:  J Parasit Dis        ISSN: 0971-7196


  52 in total

1.  Fulminant cryptosporidiosis after near-drowning: a human Cryptosporidium parvum strain implicated in invasive gastrointestinal adenocarcinoma and cholangiocarcinoma in an experimental model.

Authors:  Gabriela Certad; Sadia Benamrouz; Karine Guyot; Anthony Mouray; Thierry Chassat; Nicolas Flament; Laurence Delhaes; Valerie Coiteux; Baptiste Delaire; Marleen Praet; Claude Cuvelier; Pierre Gosset; Eduardo Dei-Cas; Colette Creusy
Journal:  Appl Environ Microbiol       Date:  2012-01-13       Impact factor: 4.792

2.  Characterization of a dexamethasone-treated rat model of cryptosporidial infection.

Authors:  J E Rehg; M L Hancock; D B Woodmansee
Journal:  J Infect Dis       Date:  1988-12       Impact factor: 5.226

Review 3.  Treatment of cryptosporidiosis: do we know what we think we know?

Authors:  Miguel M Cabada; A Clinton White
Journal:  Curr Opin Infect Dis       Date:  2010-10       Impact factor: 4.915

4.  In vitro evaluation of the suppressive effect of chitosan/poly(vinyl alcohol) microspheres on attachment of C. parvum to enterocytic cells.

Authors:  Asteria Luzardo Álvarez; Estefanía Blanco García; Florentina Guerrero Callejas; Hipólito Gómez Couso; José Blanco Méndez
Journal:  Eur J Pharm Sci       Date:  2012-06-16       Impact factor: 4.384

Review 5.  The evolution of respiratory Cryptosporidiosis: evidence for transmission by inhalation.

Authors:  Jerlyn K Sponseller; Jeffrey K Griffiths; Saul Tzipori
Journal:  Clin Microbiol Rev       Date:  2014-07       Impact factor: 26.132

6.  A new approach for targeting to Cryptosporidium parvum using mucoadhesive nanosuspensions: research and applications.

Authors:  O Kayser
Journal:  Int J Pharm       Date:  2001-02-19       Impact factor: 5.875

7.  Dose response of Cryptosporidium parvum in outbred neonatal CD-1 mice.

Authors:  G R Finch; C W Daniels; E K Black; F W Schaefer; M Belosevic
Journal:  Appl Environ Microbiol       Date:  1993-11       Impact factor: 4.792

8.  Cryptosporidium parvum infection in SCID mice infected with only one oocyst: qPCR assessment of parasite replication in tissues and development of digestive cancer.

Authors:  Sadia Benamrouz; Karine Guyot; Sophie Gazzola; Anthony Mouray; Thierry Chassat; Baptiste Delaire; Magali Chabé; Pierre Gosset; Eric Viscogliosi; Eduardo Dei-Cas; Colette Creusy; Valerie Conseil; Gabriela Certad
Journal:  PLoS One       Date:  2012-12-13       Impact factor: 3.240

Review 9.  Drug delivery and nanoparticles:applications and hazards.

Authors:  Wim H De Jong; Paul J A Borm
Journal:  Int J Nanomedicine       Date:  2008

Review 10.  Looking for Cryptosporidium: the application of advances in detection and diagnosis.

Authors:  Rachel M Chalmers; Frank Katzer
Journal:  Trends Parasitol       Date:  2013-04-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.